Adjuvant denosumab in early breast cancer - Authors' reply
Lancet Oncol
.
2020 Mar;21(3):e125.
doi: 10.1016/S1470-2045(20)30099-1.
Authors
Robert Coleman
1
,
Ying Zhou
2
,
Arlene Chan
3
;
D-CARE investigators
Affiliations
1
Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2SJ, UK. Electronic address:
[email protected]
.
2
Amgen, Thousand Oaks, CA, USA.
3
Breast Cancer Research Centre Western Australia and School of Medicine, Curtin University, Perth, WA, Australia.
PMID:
32135109
DOI:
10.1016/S1470-2045(20)30099-1
No abstract available
Publication types
Letter
Comment
MeSH terms
Aromatase Inhibitors
Bone Density Conservation Agents*
Denosumab*
Substances
Aromatase Inhibitors
Bone Density Conservation Agents
Denosumab